Stephane Esnault1, Mehdi Khosravi1, Elizabeth A Kelly1, Lin Ying Liu1, Yury A Bochkov2, Matthew C Tattersall3, Nizar N Jarjour1. 1. Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, the University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI, USA. 2. Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 3. Department of Medicine, Division of Cardiovascular Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Abstract
BACKGROUND: In asthma, IL-6 is a potential cause of enhanced inflammation, tissue damage and airway dysfunction. IL-6 signalling is regulated by its receptor, which is composed of two proteins, IL-6R and GP130. In addition to their membrane form, these two proteins may be found as extracellular soluble forms. The interaction of IL-6 with soluble IL-6R (sIL-6R) can trigger IL-6 trans-signalling in cells lacking IL-6R. Conversely, the soluble form of GP130 (sGP130) competes with its membrane form to inhibit IL-6 trans-signalling. OBJECTIVES: We aimed to analyse IL-6 trans-signalling proteins in the airways of subjects after an allergen challenge. METHODS: We used a model of segmental bronchoprovocation with an allergen (SBP-Ag) in human subjects with allergy. Before and 48 h after SBP-Ag, bronchoalveolar lavages (BALs) allowed for the analysis of proteins in BAL fluids (BALFs) by ELISA, and membrane proteins on the surface of BAL cells by flow cytometry. In addition, we performed RNA sequencing (RNA-seq) and used proteomic data to further inform on the expression of the IL-6R subunits by eosinophils, bronchial epithelial cells and lung fibroblasts. Finally, we measured the effect of IL-6 trans-signalling on bronchial fibroblasts, in vitro. RESULTS: IL-6, sIL-6R, sGP130 and the molar ratio of sIL-6R/sGP130 increased in the airways after SBP-Ag, suggesting the potential for enhanced IL-6 trans-signalling activity. BAL lymphocytes, monocytes and eosinophils displayed IL-6R on their surface and were all possible providers of sIL-6R, whereas GP130 was highly expressed in bronchial epithelial cells and lung fibroblasts. Finally, bronchial fibroblasts activated by IL-6 trans-signalling produced enhanced amounts of the chemokine, MCP-1 (CCL2). CONCLUSION AND CLINICAL RELEVANCE: After a bronchial allergen challenge, we found augmentation of the elements of IL-6 trans-signalling. Allergen-induced IL-6 trans-signalling activity can activate fibroblasts to produce chemokines that can further enhance inflammation and lung dysfunction.
BACKGROUND: In asthma, IL-6 is a potential cause of enhanced inflammation, tissue damage and airway dysfunction. IL-6 signalling is regulated by its receptor, which is composed of two proteins, IL-6R and GP130. In addition to their membrane form, these two proteins may be found as extracellular soluble forms. The interaction of IL-6 with soluble IL-6R (sIL-6R) can trigger IL-6 trans-signalling in cells lacking IL-6R. Conversely, the soluble form of GP130 (sGP130) competes with its membrane form to inhibit IL-6 trans-signalling. OBJECTIVES: We aimed to analyse IL-6 trans-signalling proteins in the airways of subjects after an allergen challenge. METHODS: We used a model of segmental bronchoprovocation with an allergen (SBP-Ag) in human subjects with allergy. Before and 48 h after SBP-Ag, bronchoalveolar lavages (BALs) allowed for the analysis of proteins in BAL fluids (BALFs) by ELISA, and membrane proteins on the surface of BAL cells by flow cytometry. In addition, we performed RNA sequencing (RNA-seq) and used proteomic data to further inform on the expression of the IL-6R subunits by eosinophils, bronchial epithelial cells and lung fibroblasts. Finally, we measured the effect of IL-6 trans-signalling on bronchial fibroblasts, in vitro. RESULTS: IL-6, sIL-6R, sGP130 and the molar ratio of sIL-6R/sGP130 increased in the airways after SBP-Ag, suggesting the potential for enhanced IL-6 trans-signalling activity. BAL lymphocytes, monocytes and eosinophils displayed IL-6R on their surface and were all possible providers of sIL-6R, whereas GP130 was highly expressed in bronchial epithelial cells and lung fibroblasts. Finally, bronchial fibroblasts activated by IL-6 trans-signalling produced enhanced amounts of the chemokine, MCP-1 (CCL2). CONCLUSION AND CLINICAL RELEVANCE: After a bronchial allergen challenge, we found augmentation of the elements of IL-6 trans-signalling. Allergen-induced IL-6 trans-signalling activity can activate fibroblasts to produce chemokines that can further enhance inflammation and lung dysfunction.
Authors: Stephane Esnault; Alexander S Hebert; Nizar N Jarjour; Joshua J Coon; Deane F Mosher Journal: J Proteome Res Date: 2018-05-04 Impact factor: 4.466
Authors: Marek Lommatzsch; Peter Julius; Michael Kuepper; Holger Garn; Kai Bratke; Sabrina Irmscher; Werner Luttmann; Harald Renz; Armin Braun; J Christian Virchow Journal: J Allergy Clin Immunol Date: 2006-04-27 Impact factor: 10.793
Authors: T Hosokawa; K Kusugami; K Ina; T Ando; M Shinoda; A Imada; M Ohsuga; T Sakai; T Matsuura; K Ito; K Kaneshiro Journal: J Gastroenterol Hepatol Date: 1999-10 Impact factor: 4.029
Authors: S M Hurst; T S Wilkinson; R M McLoughlin; S Jones; S Horiuchi; N Yamamoto; S Rose-John; G M Fuller; N Topley; S A Jones Journal: Immunity Date: 2001-06 Impact factor: 31.745
Authors: Elizabeth A Kelly; Stephane Esnault; Lin Ying Liu; Michael D Evans; Mats W Johansson; Sameer Mathur; Deane F Mosher; Loren C Denlinger; Nizar N Jarjour Journal: Am J Respir Crit Care Med Date: 2017-12-01 Impact factor: 21.405
Authors: Michael C Peters; Kelly Wong McGrath; Gregory A Hawkins; Annette T Hastie; Bruce D Levy; Elliot Israel; Brenda R Phillips; David T Mauger; Suzy A Comhair; Serpil C Erzurum; Mats W Johansson; Nizar N Jarjour; Andrea M Coverstone; Mario Castro; Fernando Holguin; Sally E Wenzel; Prescott G Woodruff; Eugene R Bleecker; John V Fahy Journal: Lancet Respir Med Date: 2016-06-06 Impact factor: 30.700
Authors: Ksenija Bernau; Jonathan P Leet; Stephane Esnault; Andrea L Noll; Michael D Evans; Nizar N Jarjour; Nathan Sandbo Journal: J Allergy Clin Immunol Date: 2018-06-21 Impact factor: 10.793
Authors: O Dienz; J G Rud; S M Eaton; P A Lanthier; E Burg; A Drew; J Bunn; B T Suratt; L Haynes; M Rincon Journal: Mucosal Immunol Date: 2012-02-01 Impact factor: 7.313
Authors: Gail M Gauvreau; Beth E Davis; Guy Scadding; Louis-Philippe Boulet; Leif Bjermer; Adam Chaker; Donald W Cockcroft; Barbro Dahlén; Wyste Fokkens; Peter Hellings; Nikolaos Lazarinis; Paul M O'Byrne; Ellen Tufvesson; Santiago Quirce; Maurits Van Maaren; Frans H de Jongh; Zuzana Diamant Journal: Eur Respir J Date: 2022-08-25 Impact factor: 33.795
Authors: Ksenija Bernau; Jonathan P Leet; Heather Floerke; Ellen M Bruhn; Andrea L Noll; Ivy S McDermott; Stephane Esnault; Nizar N Jarjour; Nathan Sandbo Journal: Cells Date: 2021-03-02 Impact factor: 6.600